Abstract
The hepatic transporters OATP1B1 and OATP1B3 contribute (to varying degrees, depending on the drug) to the uptake of many anionic drugs, including several of the widely used statins. Because statins are prescribed for many patients and the consequences of pharmacokinetic interactions with uptake inhibitors can be severe (even fatal), the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require that all NCEs be evaluated as inhibitors of OATP1B1 and OATP1B3. In addition, if hepatic clearance is expected to be a major pathway of elimination of an NCE, it must also be evaluated as a substrate of both transporters. Cell-based assays with over-expressing cell lines are useful for screening both substrates (based on uptake of the test compound) and inhibitors (based on interference with the uptake of a probe substrate by the test compound). The approach will be illustrated with real data, and subtle but important technical details will be discussed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Niemi M (2007) Role of OATP transporters in the disposition of drugs. Pharmacogenomics 8(7):787–802
Shitara Y, Hirano M, Sato H, Sugiyama Y (2004) Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311(1):228–236
Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, Eichelbaum M, Kivisto KT, Neuvonen PJ (2005) Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 77:468–478
Kalliokoski A, Niemi M (2009) Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158(3):693–705
Staffa JA, Chang J, Green G (2002) Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346:539–540
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (2012) Draft guidance for industry. Drug interaction studies—study design, data analysis, implications for dosing, and labeling recommendations. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf
European Medicines Agency, Committee for Human Medicinal Products (CHMP) (2012) Guideline on the investigation of drug interactions. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this protocol
Cite this protocol
Miezeiewski, B., McLaughlin, A. (2014). In Vitro Characterization of Hepatic Transporters OATP1B1 and OATP1B3. In: Caldwell, G., Yan, Z. (eds) Optimization in Drug Discovery. Methods in Pharmacology and Toxicology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-742-6_23
Download citation
DOI: https://doi.org/10.1007/978-1-62703-742-6_23
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-741-9
Online ISBN: 978-1-62703-742-6
eBook Packages: Springer Protocols